uniQure N.V.
NASDAQ:QURE 4:00:00 PM EDT
| Market Cap (Intraday) | 288.29M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.24 |
| 50-Day MA | $6.04 |
| 200-Day MA | $5.72 |
uniQure N.V. Stock, NASDAQ:QURE
Paasheuvelweg 25a, Amsterdam, Noord-Holland 1105 BP
Netherlands
Phone: +31.20.240.60.00
Number of Employees: 480
Description
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.